Aqueous macrophages contribute to conserved CCL2 and CXCL10 gradients in uveitis
-
Published:2023-12
Issue:
Volume:
Page:100453
-
ISSN:2666-9145
-
Container-title:Ophthalmology Science
-
language:en
-
Short-container-title:Ophthalmology Science
Author:
Lin Joseph B.ORCID, Pepple Kathryn L., Concepcion Christian, Korshunova Yulia, Paley Michael A.ORCID, Paley Grace L.ORCID, Laurent JenniferORCID, Apte Rajendra S.ORCID, Hassman Lynn M.ORCID
Reference38 articles.
1. Jaffe, G.J., Dick, A.D., Brézin, A.P., Nguyen, Q.D., Thorne, J.E., Kestelyn, P., Barisani-Asenbauer, T., Franco, P., Heiligenhaus, A., Scales, D., et al. (2016). Adalimumab in patients with active noninfectious uveitis. New England Journal of Medicine. 10.1056/NEJMoa1509852. 2. Ramanan, A.V., Dick, A.D., Guly, C., McKay, A., Jones, A.P., Hardwick, B., Lee, R.W.J., Smyth, M., Jaki, T., and Beresford, M.W. (2020). Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. The Lancet Rheumatology 2, e135–e141. 10.1016/S2665-9913(20)30008-4. 3. Secukinumab in the treatment of noninfectious uveitis: Results of three randomized, controlled clinical trials;Dick;Ophthalmology,2013 4. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis;Curnow;Invest Ophthalmol Vis Sci,2005 5. Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis;El-Asrar;Clinical Immunology,2011
|
|